GSK-A1 是III 型磷脂酰肌醇 4-激酶 PI4KA选择性抑制剂，pIC50为 8.5-9.8，抑制 PtdIns(4,5)P2 再合成，IC50约为 3 nM。GSK-A1有效降低 PtdIns(4)P 的水平，而对 PtdIns(4,5)P2 没影响。GSK-A1在抗丙型肝炎病毒方面有研究的潜力。

GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.

GSK-A1 is a selective?type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα)?inhibitor with a?pIC50?of 8.5-9.8[3]. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2[3].

1416334-69-4

C29H27FN6O4S

574.63

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years